LEXICON PHARMACEUTICALS INC. - COMMON STOCK

Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

31 May 2022 08:00:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update

05 May 2022 06:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022

29 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference

07 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Lexicon Welcomes New Guidelines for the Management of Heart Failure

04 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)

02 Apr 2022 12:15:00 By Nasdaq GlobeNewswire

New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)

21 Mar 2022 08:01:00 By Nasdaq GlobeNewswire

Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin

17 Mar 2022 16:14:31 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update

28 Feb 2022 06:01:00 By Nasdaq GlobeNewswire

Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022

28 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022

25 Feb 2022 21:03:49 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference

13 Jan 2022 09:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

30 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference

15 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Lexicon’s Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data

14 Nov 2021 08:35:00 By Nasdaq GlobeNewswire

New Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function

09 Nov 2021 08:00:04 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update

03 Nov 2021 16:02:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 3, 2021

28 Oct 2021 19:27:58 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

15 Sep 2021 08:00:01 By Nasdaq GlobeNewswire